Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03989414
Recruitment Status : Recruiting
First Posted : June 18, 2019
Last Update Posted : September 16, 2021
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:
This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: CC-92480 Drug: Bortezomib Drug: Dexamethasone Drug: Daratumumab Drug: Carfilzomib Drug: Elotuzumab Drug: Isatuximab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 408 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Actual Study Start Date : September 30, 2019
Estimated Primary Completion Date : September 30, 2023
Estimated Study Completion Date : January 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Cohort A: CC-92480 with bortezomib and dexamethasone
  • Oral CC-92480 at specified cohort A dose administered over a 21-day cycle
  • Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle
  • Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle in the first 8 cycles and on days 1, 2, 8 and 9 after Cycle 8
Drug: CC-92480
CC-92480

Drug: Bortezomib
Bortezomib

Drug: Dexamethasone
Dexamethasone

Experimental: Cohort C: CC-92480 with carfilzomib and dexamethasone
  • Oral CC-92480 at specified cohort C dose administered over a 28-day cycle
  • Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle
  • Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) administered over a 28-day cycle
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Carfilzomib
Carfilzomib

Experimental: Cohort H: CC-92480 with elotuzumab and dexamathasone
  • Oral CC-92480 at specified cohort H dose administered over a 28-day cycle
  • Intravenous ELO 10 mg/kg then 20 mg/kg administered over a 28-day cycle
  • Oral (28 mg) and IV (8 mg) dexamethasone for total 36 mg/day (oral [8 mg] and IV [8 mg] dexamethasone for total 16 mg/day for subjects > 75 years old) on ELO dosing days, and oral dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) on non-ELO dosing days, administered over a 28-day cycle
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Elotuzumab
Elotuzumab

Experimental: Cohort I: CC-92480 with isatuximab and dexamathasone
  • Oral CC-92480 at specified cohort I dose administered over a 28-day cycle
  • Intravenous ISA 10 mg/kg administered over a 28-day cycle
  • Oral/IV dexamethasone 40 mg weekly (20 mg weekly for subjects > 75 years old)
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Isatuximab
Isatuximab

Experimental: Cohort D: CC-92480 with bortezomib and dexamethasone
  • Oral CC-92480 at RP2D administered over a 21-day cycle
  • Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle
  • Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle in the first 8 cycles and on days 1, 2, 8 and 9 after Cycle 8
Drug: CC-92480
CC-92480

Drug: Bortezomib
Bortezomib

Drug: Dexamethasone
Dexamethasone

Experimental: Cohort F: CC-92480 with carfilzomib and dexamethasone
  • Oral CC-92480 at RP2D administered over a 28-day cycle
  • Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle
  • Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) administered over a 28-day cycle
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Carfilzomib
Carfilzomib

Experimental: Cohort J: CC-92480 with elotuzumab and dexamathasone
  • Oral CC-92480 at RP2D administered over a 28-day cycle
  • Intravenous ELO 10 mg/kg then 20 mg/kg administered over a 28-day cycle
  • Oral (28 mg)/IV (8 mg) dexamethasone for total 36 mg/day (oral [8 mg]/IV [8 mg] dexamethasone for total 16 mg/day for subjects > 75 years old) on ELO dosing days, and oral dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) on non-ELO dosing days, administered over a 28-day cycle
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Elotuzumab
Elotuzumab

Experimental: Cohort K: CC-92480 with isatuximab and dexamathasone
  • Oral CC-92480 at RP2D administered over a 28-day cycle
  • Intravenous ISA 10 mg/kg administered over a 28-day cycle
  • Oral/IV dexamethasone 40 mg weekly (20 mg weekly for subjects > 75 years old)
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Isatuximab
Isatuximab

Experimental: Cohort G: CC-92480 with bortezomib and dexamethasone
  • Oral CC-92480 at RP2D administered over a 21-day cycle
  • Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle up to Cycle 6
  • Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle up to Cycle 6
Drug: CC-92480
CC-92480

Drug: Bortezomib
Bortezomib

Drug: Dexamethasone
Dexamethasone

Experimental: Subcohort B1: CC-92480 with daratumumab and dexamethasone
  • Oral CC-92480 at specified cohort dose administered over a 28-day cycle
  • Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
  • Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Daratumumab
Daratumumab

Experimental: Subcohort B2: CC-92480 with daratumumab and dexamethasone
  • Oral CC-92480 at specified cohort dose administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards
  • Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
  • Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight, administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Daratumumab
Daratumumab

Experimental: Subcohort B3: CC-92480 with daratumumab and dexamethasone
  • Oral CC-92480 at specified cohort B dose administered over a 28-day cycle
  • Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
  • Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Daratumumab
Daratumumab

Experimental: Subcohort E1: CC-92480 with daratumumab and dexamethasone
  • Oral CC-92480 at RP2D administered over a 28-day cycle
  • Either IV DARA administered at a dose of 16 mg/kg or SC DARA administered at a dose of 1800 mg over 3 to 5 minutes
  • Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Daratumumab
Daratumumab

Experimental: Subcohort E2: CC-92480 with daratumumab and dexamethasone
  • Oral CC-92480 at RP2D administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards
  • Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
  • Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight, administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Daratumumab
Daratumumab

Experimental: Subcohort E3: CC-92480 with daratumumab and dexamethasone
  • Oral CC-92480 at RP2D administered over a 28-day cycle
  • Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes
  • Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle
Drug: CC-92480
CC-92480

Drug: Dexamethasone
Dexamethasone

Drug: Daratumumab
Daratumumab




Primary Outcome Measures :
  1. Dose-limiting Toxicities (DLT) [ Time Frame: UP to approximately 2 years from enrollment ]
    Number of participants with DLTs in the first cycle of the treatment

  2. Adverse Events (AEs) [ Time Frame: From first subject first visit until 28 days after the last subject discontinues study treatment. ]
    Type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to study treatment

  3. Overall response rate (ORR) [ Time Frame: UP to approximately 3 years from enrollment ]
    Defined as the proportion of subjects who achieve partial response (PR)or better according to the International Myeloma Working Group (IMWG) Uniform Response Criteria .


Secondary Outcome Measures :
  1. Time-to-response (TTR) [ Time Frame: UP to approximately 3 years from enrollment ]
    Time from first dose to the first documentation of response (PR or greater)

  2. Duration of response (DOR) [ Time Frame: Up to approximately 3 years from enrollment ]
    Time from the first documentation of response (PR or greater) to the first documentation of progressive disease (PD) or death

  3. Complete Response (CR) rate [ Time Frame: Up to approximately 3 years from enrollment ]
    Percentage of subjects who achieved CR or better according to IMWG Uniform Response Criteria

  4. Very good partial response (VGPR) rate [ Time Frame: Up to approximately 3 years from enrollment ]
    Percentage of subjects who achieved VGPR or better according to IMWG Uniform Response Criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Key Inclusion criteria

  • Subject is ≥ to 18 years of age the time of signing the informed consent form (ICF).
  • Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.

For subjects in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:

  • Subject has documented diagnosis of MM and measurable disease, defined as: M-protein quantities ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) and/or Serum free light chain (FLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda (κ/λ) ratio in subjects without measurable disease in the serum or urine
  • Subject has received 2 to 4 (for Cohorts A, B, C, H, and I) or 1 to 3 (Cohorts D, E, and F) or ≥ 2 (Cohorts J and K) prior anti-myeloma regimens.
  • Subject has received prior treatment with a lenalidomide-containing regimen for at least 2 consecutive cycles.
  • Subject achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen.
  • Subject must have documented disease progression during or after their last anti-myeloma regimen.

For Cohorts J and K:

  • Subject has also received prior treatment with a proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) given alone or in combination for at least 2 consecutive cycles AND
  • Subject has failed therapy with lenalidomide and a proteasome inhibitor, given alone or in combination, defined as progression on or within 60 days of treatment, or disease progression within 6 months after achieving at least a partial response.

Subject is refractory (progressed on or within 60 days of treatment) to their last treatment.

  • Cohort F: Prior therapy with a proteasome inhibitor (PI), excluding carfilzomib, is allowed as long as the subject had at least a PR to prior PI therapy, was not removed from PI therapy due to toxicity, and will have at least a 6-month PI treatment-free interval from last dose received until first study treatment (Subjects may receive maintenance therapy with drugs that are not in PI class during this 6-month treatment free interval).
  • For subjects in Cohort G, the following inclusions will also apply:

Considered by the investigator to be eligible for high-dose chemotherapy and autologous stem cell transplantation (ASCT) according to the institution's criteria based on age, medical history, cardiac and pulmonary status, overall health and condition, co-morbid condition(s), physical examination, and laboratory.

Subject must have documented diagnosis with previously untreated symptomatic MM AND have measurable disease, as assessed by central laboratory.

Exclusion Criteria:

Key Exclusion criteria

  • Subject has any of the following laboratory abnormalities:

    1. Absolute neutrophil count (ANC) < 1,000/µL (for Phase 1 without growth factor support for ≥ 7 days [≥ 14 days for pegfilgrastim])
    2. Platelet count: < 75,000/µL (it is not permissible to transfuse a subject to reach this level)
    3. Hemoglobin < 8 g/dL (< 4.9 mmol/L)
    4. Creatinine clearance (CrCl) < 45 mL/min (< 30 mL/min for Cohort G)
    5. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L)
    6. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN
    7. Serum total bilirubin > 1.5 x ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome
    8. Prothrombin time (PT)/international normalized ratio (INR) 1.5 x ULN or partial thromboplastin time (PTT) 1.5 x ULN, (for subjects not receiving therapeutic anticoagulation).
  • Subject has peripheral neuropathy ≥ Grade 2
  • Subject with gastrointestinal disease that may significantly alter the absorption of CC-92480.
  • Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years with the exception of the following non-invasive malignancies: Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative.
  • Subject has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis.
  • Subject with known central nervous system (CNS) involvement with myeloma.
  • Subject has received immunosuppressive medication within the last 14 days of initiating study treatment. The following are exceptions to this criterion:

Intranasal, inhaled, topical or local corticosteroid injections (eg, intra-articular injection).

  • Systemic corticosteroids at doses that do not exceed 10 mg/day of prednisone or the equivalent.
  • Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication).
  • Subject has impaired cardiac function or clinically significant cardiac disease, including any of the following:

    1. Left ventricular ejection fraction (LVEF) < 45% as determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan at Screening.

      Complete left bundle branch, bifascicular block or other clinically significant abnormal electrocardiogram (ECG) finding at Screening

    2. A prolongation of QT interval on Screening ECG as defined by repeated demonstration of a QTc interval > 470 milliseconds (msec) using Fridericia's QT correction formula; a history of or current risk factors for torsades de pointes (eg, heart failure, hypokalemia, or a family history of Long QT Syndrome); and concurrent administration of medications that prolong the QT/QTc interval Congestive heart failure (New York Heart Association Class III or IV).
    3. Myocardial infarction within 12 months prior to starting study treatment. Unstable or poorly controlled angina pectoris, including the Prinzmetal variant of angina pectoris
    4. History of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, pericardial disease or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker
    5. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment.
    6. Concurrent administration of strong CYP3A modulators; concurrent administration of proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, pantoprazole) ≤ 2 weeks prior to starting CC-92480.
  • Subject is a female who is pregnant, nursing or breastfeeding, or who intends to become pregnant during the participation in the study.

Subject is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis A or C.

  • Subject has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, pomalidomide, BTZ (for Cohorts A, D and G), DARA (for Cohorts B and E), CFZ (for Cohorts C and F), ELO (for Cohorts H and J), ISA (for Cohorts I and K), or dexamethasone.
  • Subject has known or suspected hypersensitivity to the excipients contained in the formulation of CC-92480, BTZ (for Cohorts A, D and G), DARA (for Cohorts B and E), CFZ (for Cohorts C and F), ELO (for Cohorts H and J), ISA (for Cohorts I and K), or dexamethasone.
  • Contraindications to the standard treatment regimens, per local prescribing information.
  • Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.

For subjects in Cohorts A, B, C, D, E, F, H, I, J, and K, the following exclusions will also apply:

  • Subject received any of the following within the last 14 days of initiating study treatment:

    1. Plasmapheresis
    2. Major surgery (as defined by the Investigator)
    3. Radiation therapy other than local therapy for myeloma associated bone lesions
    4. Use of any systemic anti-myeloma drug therapy
    5. Cohorts A and D: Subjects who had progression during treatment or within 60 days of the last dose of BTZ or discontinued BTZ due to toxicity.
    6. Cohorts B and I: Subjects who had progression during treatment or within 60 days of the last dose of DARA/ISA or discontinued DARA/ISA due to toxicity.
    7. Cohort C: Subjects who had progression during treatment or within 60 days of the last dose of CFZ or discontinued CFZ due to toxicity.
    8. Cohorts D, E, F, J, and K: Previous treatment with pomalidomide (POM).
    9. Cohorts E and K: Previous treatment with DARA or ISA.
    10. Cohort F: Previous treatment with CFZ.
    11. Subject used any investigational agents within 28 days or 5 half-lives (whichever is longer) of initiating study treatment.
    12. Subject has received previous allogeneic stem cell transplantation or received autologous stem cell transplantation within 12 weeks prior to starting study treatment.
    13. Cohorts B, E, I, and K: Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% of predicted normal. Note that forced expiratory testing (FEV1) is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is < 50% of predicted normal.
    14. Cohorts B, E, I, and K: Subject has known moderate or severe persistent asthma, or currently has uncontrolled asthma of any classification.
    15. Cohorts C and F: Subject has mild hepatic impairment defined as elevated bilirubin 1.0 but < 1.5 x ULN or normal bilirubin with any elevation of AST.
    16. Cohort H: Subjects who had progression during treatment or within 60 days of the last dose of ELO or discontinued ELO due to toxicity
    17. Cohort J: Previous treatment with ELO

      For subjects in Cohort G, the following exclusion criteria will also apply:

  • Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid [ie, less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 14 days of initiating study treatment]).

For subjects in all cohorts:

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 14 days for mild or asymptomatic infections or within 28 days for severe/critical illness prior to enrollment.
  • Acute symptoms must have resolved and there must be no sequelae that would place the subject at a higher risk of clinically significant complications from receiving study treatment, based on the Investigator's assessment in consultation with the Sponsor Medical Monitor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03989414


Contacts
Layout table for location contacts
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@bms.com

Locations
Show Show 49 study locations
Sponsors and Collaborators
Celgene
Investigators
Layout table for investigator information
Study Director: Alessandro Ghiddi, MD Celgene
Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT03989414    
Other Study ID Numbers: CC-92480-MM-002
U1111-1233-5619 ( Other Identifier: WHO )
2018-004767-31 ( EudraCT Number )
First Posted: June 18, 2019    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Information relating to our policy on data sharing and the process for requesting data can be found at the following link:

https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: See Plan Description
Access Criteria: See Plan Description
URL: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Celgene:
Relapsed or Refractory Multiple Myeloma
Newly Diagnosed Multiple Myeloma
Multiple Myeloma
CC-92480
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Bortezomib
Daratumumab
Elotuzumab
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents